Amgen Inc. Company Profile

Aggregated data from the web about Amgen Inc.

Company Name	Amgen Inc.
Website	https://www.amgen.com
Snippet	Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
Type	Public
Founded	1980
Revenue	US$23.362 billion (2019)
Website	amgen.com
Formerly	Applied Molecular Genetics(1980–1983)
Industry	Biotechnology
Products	Aimovig, Aranesp, Blincyto, Epogen, Kineret, Enbrel, Kyprolis, Neulasta, Neupogen, Nplate, Parsabiv, Prolia, Repatha, Sensipar/Mimpara, Vectibix and Xgeva.
Traded as	NASDAQ: AMGN, NASDAQ-100 component, DJIA component, S&P 100 component, S&P 500 component
Key people	Robert A. Bradway(Chairman, President, and CEO)
Net income	US$7.842 billion (2019)
Headquarters	Thousand Oaks, California, U.S.
Total assets	US$59.707 billion (2019)
Total equity	US$9.673 billion (2019)
Operating income	US$9.674 billion (2019)
Number of employees	22,000 (February 2020)[1]

Amgen Inc. is part of the United States company list

Amgen Inc. is part of the Biotechnology company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.